N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
Metrics to compare | N4P | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipN4PPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.5x | −2.4x | −0.5x | |
PEG Ratio | −0.09 | −0.02 | 0.00 | |
Price/Book | 5.8x | 1.7x | 2.6x | |
Price / LTM Sales | 514.3x | 2.5x | 3.3x | |
Upside (Analyst Target) | - | 61.5% | 43.5% | |
Fair Value Upside | Unlock | 16.1% | 6.9% | Unlock |